ASCERTAIN - IMPACT OF INTRAVENOUS ABATACEPT ON SYNOVITIS, OSTEITIS AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE: A RANDOMISED CONTROLLED TRIAL

DEAD

Serial Number

85525635

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Jan 26, 2012

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

ASCERTAIN - IMPACT OF INTRAVENOUS ABATACEPT ON SYNOVITIS, OSTEITIS AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE: A RANDOMISED CONTROLLED TRIAL Trademark

Serial Number: 85525635

ASCERTAIN - IMPACT OF INTRAVENOUS ABATACEPT ON SYNOVITIS, OSTEITIS AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE: A RANDOMISED CONTROLLED TRIAL is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on January 26, 2012. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Trademark Classes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,814 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Legal Representation

Attorney of Record

Marilyn F. Kelly

2,565 trademarks filed View all →

Trademark Details

Filing Date

January 26, 2012

Registration Date

Not Registered

Goods & Services

Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use for pharmaceutical research and development